Abstract

R Niven has received an unrestricted grant of £10,000 from Novartis in 2010 towards development of clinical services at the University Hospital of South Manchester. He has run preceptorship programmes in 2015 and 2106. These programmes have resulted in payment to the University Hospital of south Manchester for amounts not exceeding £10,000. Dr Niven has also performed lecturing at Pharmaceutically sponsored meetings for the following pharmaceutical companies in the last 3 years:- Astra Zeneca (<£1,000), Boehringer Ingelheim (<£2,000) Boston scientific (<£5,000) Chiesi (<£1,000), Novartis < £10,000, Napp (<£2,000), Teva (<£2,000). Dr Niven has sat on advisory boards for the following companies in the last 3 years, (Astra Zeneca, Boehringer Ingelheim, Boston scientific, Chiesi, GSK, Novartis Vectura and Teva), receiving reimbursement not exceeding £5,000 per company. Dr Niven has received sponsorship support to attend international academic meetings from Astra Zeneca, Boehringer ingelheim, Novartis, GSK, Chiesi and TEVA. Dr Niven, (or any members of his family) has no shares or any pecuniary interest in any pharmaceutical industry and has no share holdings or dividends and is not a paid consultant for any company.

D Saralaya has no conflicts of interest pertaining to this abstract

R Chaudhuri has been a member of advisory board meetings for Novartis, Astraeneca, GSK and Teva, been invited to international conferences by Novartis, Boehringer, AstraZeneca and Napp and received educational research grants from Novartis and Aerocrine.

M Masoli attended a Novartis advisory board meeting.

I Clifton has received honoria from Novartis, and GSK. He has received travel grants to attend educational meetings from Novartis, GSK, Gilead and AstraZeneca.

AH Mansur has received personal and institutional payments for speaking, participation in advisory board meetings and other education activities from several pharmaceutical companies that include AZ, GSK, BI, Novartis, Teva, NAPP, Chiesi

S Hollywood Employee at Novartis. This study was funded by Novartis, who participated in the study design, interpretation of data, and review and approval of the abstract.

S Mclain-Smith employee of pH Associates; carried out data analysis and provided medical writing support.

A Menzies-Gow has attended advisory boards for GlaxoSmithKline, Novartis, AstraZeneca, Boehringer Ingelheim, and Teva. He has received speaker fees from Novartis, AstraZeneca, Vectura, Boehringer Ingelheim, and Teva. He has received clinical trial funding from AstraZeneca and has participated in research with Hoffmann La Roche, GlaxoSmithKline, and Boehringer Ingelheim, for which his institution has been remunerated. He has attended international conferences with Napp and AstraZeneca and has consultancy agreements with AstraZeneca and Vectura